187 related articles for article (PubMed ID: 22252658)
41. Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy.
Passadouro M; Faneca H
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187371
[TBL] [Abstract][Full Text] [Related]
42. Molecular landscape of pancreatic cancer: implications for current clinical trials.
Heestand GM; Kurzrock R
Oncotarget; 2015 Mar; 6(7):4553-61. PubMed ID: 25714017
[TBL] [Abstract][Full Text] [Related]
43. Current Molecular and Genetic Aspects of Pancreatic Cancer, the Role of Metastasis Associated Proteins (MTA): A Review.
Pavlidis ET; Pavlidis TE
J Invest Surg; 2018 Feb; 31(1):54-66. PubMed ID: 28060554
[TBL] [Abstract][Full Text] [Related]
44. The Past, Present, and Future of Pancreatic Cancer Clinical Trials.
Matrisian LM; Berlin JD
Am Soc Clin Oncol Educ Book; 2016; 35():e205-15. PubMed ID: 27249725
[TBL] [Abstract][Full Text] [Related]
45. Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma.
Audisio RA; Veronesi P; Maisonneuve P; Chiappa A; Andreoni B; Bombardieri E; Geraghty JG
Surg Oncol; 1996 Apr; 5(2):49-63. PubMed ID: 8853239
[TBL] [Abstract][Full Text] [Related]
46. Identifying molecular markers for the early detection of pancreatic neoplasia.
Goggins M
Semin Oncol; 2007 Aug; 34(4):303-10. PubMed ID: 17674958
[TBL] [Abstract][Full Text] [Related]
47. Genomics and pharmacogenomics of pancreatic adenocarcinoma.
Lowery MA; O'Reilly EM
Pharmacogenomics J; 2012 Feb; 12(1):1-9. PubMed ID: 22186617
[TBL] [Abstract][Full Text] [Related]
48. High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.
Liau SS; Whang E
Surgeon; 2009 Oct; 7(5):297-306. PubMed ID: 19848064
[TBL] [Abstract][Full Text] [Related]
49. Early diagnosis of pancreatic cancer: challenges and new developments.
Kaur S; Baine MJ; Jain M; Sasson AR; Batra SK
Biomark Med; 2012 Oct; 6(5):597-612. PubMed ID: 23075238
[TBL] [Abstract][Full Text] [Related]
50. Immunoisolation of pancreatic epithelial cells from endoscopic ultrasound-guided fine needle aspirates with magnetic beads for downstream molecular application.
Afify A; Huang EC; Jeong M; Urayama S
Diagn Cytopathol; 2016 Jan; 44(1):32-8. PubMed ID: 26466823
[TBL] [Abstract][Full Text] [Related]
51. Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma.
Llop E; E Guerrero P; Duran A; Barrabés S; Massaguer A; José Ferri M; Albiol-Quer M; de Llorens R; Peracaula R
World J Gastroenterol; 2018 Jun; 24(24):2537-2554. PubMed ID: 29962812
[TBL] [Abstract][Full Text] [Related]
52. Detection and proteomic characterization of extracellular vesicles in human pancreatic juice.
Osteikoetxea X; Benke M; Rodriguez M; Pálóczi K; Sódar BW; Szvicsek Z; Szabó-Taylor K; Vukman KV; Kittel Á; Wiener Z; Vékey K; Harsányi L; Szűcs Á; Turiák L; Buzás EI
Biochem Biophys Res Commun; 2018 Apr; 499(1):37-43. PubMed ID: 29550476
[TBL] [Abstract][Full Text] [Related]
53. Prognostic factors in ductal pancreatic cancer.
Yeo CJ; Cameron JL
Langenbecks Arch Surg; 1998 Apr; 383(2):129-33. PubMed ID: 9641885
[TBL] [Abstract][Full Text] [Related]
54. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
55. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
56. Current management of pancreatic carcinoma.
Lillemoe KD
Ann Surg; 1995 Feb; 221(2):133-48. PubMed ID: 7531966
[TBL] [Abstract][Full Text] [Related]
57. Surgical management of hereditary pancreatic cancer.
Davis B; Lowy AM
Med Clin North Am; 2000 May; 84(3):749-59. PubMed ID: 10872430
[TBL] [Abstract][Full Text] [Related]
58. [Recommendations for diagnosis, staging and treatment of pancreatic cancer (Part I). Grupo Español de Consenso en Cáncer de Páncreas].
Navarro S; Vaquero E; Maurel J; Bombí JA; De Juan C; Feliu J; Fernández Cruz L; Ginés A; Girela E; Rodríguez R; Sabater L; ; ; ; ; ;
Med Clin (Barc); 2010 May; 134(14):643-55. PubMed ID: 20346471
[No Abstract] [Full Text] [Related]
59. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
60. Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer.
Melson J; Li Y; Cassinotti E; Melnikov A; Boni L; Ai J; Greenspan M; Mobarhan S; Levenson V; Deng Y
Int J Cancer; 2014 Jun; 134(11):2656-62. PubMed ID: 24288256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
